Effect of Exenatide on Liver and Heart Fat and Inflammation

NCT01951651 on ClinicalTrials.gov · last registry update 2016-05-16

A small phase 4 — 24 participants, against a typical 75. The sponsor logged completion for October 2012. Primary outcome, as filed: Myocardial Fat Content. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Baylor College of Medicine
Sponsor type: Other
Enrollment: 24
Started: 2010-04
Primary completion: 2012-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Myocardial Fat Content

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.